The efficacy of Povidone-iodine on adenoviral keratoconjunctivitis adenoviral keratoconjunctivitis, Povidone-iodine, sub-epithelial infiltration
Conditions
Interventions
povidone iodine 1% eye drop q 6 h for 5 days,povidone iodine 0.6% eye drop q 6 h for 5 days,artificial tears q 6 h for 5 days
Active Comparator Drug,Active Comparator Drug,Active Comparator Drug
povidone iodine 1% eye drop,povidone iodine 0.6% eye drop,artificial tears
Sponsors
AJA university of medical sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients aged 18 or older with clinical suspicion of acute adenoviral keratoconjunctivitis and those with disease duration of up to 3 days were included. Exclusion criteria were as follows: previous treatment, allergy to iodine or steroid, known steroid-induced glaucoma, history of herpes simplex keratitis, pregnancy. In addition, patients in which adenovirus was not identified by PCR were excluded (although treatment was not delayed while waiting for results).
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows: previous treatment, allergy to iodine or steroid, known steroid-induced glaucoma, history of herpes simplex keratitis, pregnancy. In addition, patients in which adenovirus was not identified by PCR were excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| duration of acute disease 0,3,5,7,10,15,20 days after intervention physical examination,subepithelial infiltration 15,20 days after intervention physical examination,symblepharon one month after intervention physical examination | — |
Secondary
| Measure | Time frame |
|---|---|
| dry eye symptoms 1,3 month after intervantion physical examination,eye discomfort 1,3 month after intervantion history taking ,type of adenovirus 0 days PCR test,blurred vision 0 day and 1,3 month after intervantion snellen chart | — |
Countries
Iran
Contacts
Public ContactAli Makateb
AJAUMS
Outcome results
None listed